2026 Q1 -tulosraportti
20 päivää sitten
‧29 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 825 | - | - | ||
| 279 | - | - | ||
| 15 | - | - | ||
| 350 | - | - | ||
| 225 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 172 592 | 172 592 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 172 592 | 172 592 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·4 t sittenOnly for those of you who share my interest in finding out what hospitals do to avoid being sued. Everyone else stop reading. Now the penny has finally dropped for me. I have finally gotten an answer as to why it is best to sell the NGAL test as RUO in the USA at the moment. The above is a question we investors have never had answered, even though we ask about it often. Now that the FDA has done the unthinkable, kicking KDIGO's strong recommendations to the curb (see link from previous post) and due to political pressure from Donald Trump (see link from previous post) delaying the NGAL test for adults from being approved in the USA. I have dug a bit to find out if there is anything hospitals will do to avoid lawsuits from patients and relatives. Because it is not the FDA that becomes the victim of a lawsuit, it is the hospitals. Lawyers will never directly accuse a hospital of not implementing the NGAL test as long as the FDA has not approved the test, but they will accuse hospitals of not monitoring well enough, being too slow to react, etc. Lawyers will not use the words NGAL test, but everything else that revolves around the NGAL test's properties, and in this way, accuse hospitals of not being able to react as quickly as the NGAL test. As you can see, it's about large sums of money. To avoid the feared lawsuits and settlements, there is a grey zone that both BP and the hospitals are treading in on tiptoes. Hospitals large enough to have an advanced laboratory can get permission to introduce the NGAL test into their treatment systems, but only approved for research (RUO); every time hospitals use this test on their patients, it is naturally only for research. Hospitals will integrate the NGAL test into their treatment system, but only for research, naturally, to avoid lawsuits and settlements. The above also answers another wonder of mine: how can it be that there is strong growth in the USA when it is only for research? That is because those hospitals that have an advanced enough laboratory to help Bioporto in research also secretly use the test on all their other patients where the test is beneficial. The above is the reason why both PME and CB only come with some mumbling and incomprehensible words as to why RUO is good for BP's earnings. The FDA is naturally aware of this, but as long as the NGAL test saves lives and health, the bear will remain in its den.·3 t sittenSuch rubbish. It's blatantly obvious that everything you write is something you uncritically get from AI, which, so to speak, is trained in the USA, where one cannot say anything without also talking about lawsuits. In both BP and stenocare, you constantly babble about lawsuits. Only with an AI crash course in FDA did you delude yourself into thinking you understood FDA's complicated decision-making process and that on that basis you could predict that ngal would get a faster path. You were wrong because you didn't have the necessary insight to conclude as you did. No one has become a professor just by googling, either. It's not about conspiracy. It's about learning your own limitations and learning to use AI and Google with care.
·16 t sittenTo those of you who have a lot of money tied up in bioporto. Then I can't help but think that if it's going to take 2 years before anything happens with potential approvals, stock price increases, etc., then the money could be invested in many other things in the meantime? Economically speaking, it probably doesn't make much sense to have the money "standing still"? Because the stock price will probably hardly climb significantly before 2028 if things go as bioporto hopes? Anyone who wants to enlighten me on what they think? 🤔
·4 t sittenNo, I don't agree with that. The only thing that can truly destroy Bioporto at this share price level is if the adult study fails.
·4 t sitten · MuokattuPm_invest It's good to have different assessments. I now see the upcoming Kdigo as something investors attach great value to, both up and down. But I certainly find it interesting that you don't think it will affect the price. We will soon get an answer.- ·22 t sittenCongratulations to CEO, Carsten Buhl, who in approx. 6 months has delivered 2 postponements of the financial target for cash flow Original plan H2 2027 1st postponement H1 2028 2nd postponement H2 2028 How many more can Carsten possibly manage to deliver in the coming 24 months...... 1, 2 or 3? The clock is ticking and patent expiry is getting closer and closer, while BP is burning millions.·21 t sittenProgression, there is a reason why very many small investors lose money, one of them is that many small investors are not at all interested in facts but only in hearing what they want to hear.
·23 t sittenPeople can view today's announcement as positive or negative depending on why one has invested in BioPorto. I clearly choose to see it from the positive side, as FDA has indicated that the regulatory path BioPorto has followed in their pre-sub study is the right path. Since the adult area is large, very large, FDA has recommended that in the validation study, the number of test subjects be increased from 500 to 900, which will of course push the timeline and cost extra money. I note here that they do not mention an emission, but rather will save their way out of the extra 20 million and if necessary seek credit possibilities for any remainder. It is not Trump/USA against BioPorto. It is a medical professional assessment made by FDA, and of course BioPorto chooses to cooperate regarding this. If one believes in the case, it can only be seen positively, as by complying with FDA, one is more certain of approval when the time comes, precisely because of a stronger study with more test subjects involved. The next milestone is the publication of KDIGO guidelines.·22 t sittenThat's probably the only thing you don't do…you exclusively post comments that are full of speculations and guesswork and it's clear to see you do everything to belittle others and the company…without anything to back it up.- ·1 päivä sittenBioPorto plans U.S. adult validation study after feedback from the U.S. Food and Drug Administration (FDA) today at 12:28 ∙ GlobeNewswire https://www.globenewswire.com/news-release/2026/06/09/3308648/0/en/bioporto-initiates-u-s-adult-validation-study-following-u-s-food-and-drug-administration-fda-feedback.html·22 t sittenI am speechless that 3D continues to comment totally uncritically on the "big" journey and refuses to talk about risk. Watch out for your money out there and remember to be critical when you read "biased" posts in here. Let me remind you that 3D talked about SAS and the company's great future, as a shareholder (!), all while the share price was heading towards 0. He refused to acknowledge all talk about the stock potentially becoming worthless. It is shocking.·22 t sittenThere is nothing, as in absolutely nothing factual whatsoever, in your posts/comments here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
20 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·4 t sittenOnly for those of you who share my interest in finding out what hospitals do to avoid being sued. Everyone else stop reading. Now the penny has finally dropped for me. I have finally gotten an answer as to why it is best to sell the NGAL test as RUO in the USA at the moment. The above is a question we investors have never had answered, even though we ask about it often. Now that the FDA has done the unthinkable, kicking KDIGO's strong recommendations to the curb (see link from previous post) and due to political pressure from Donald Trump (see link from previous post) delaying the NGAL test for adults from being approved in the USA. I have dug a bit to find out if there is anything hospitals will do to avoid lawsuits from patients and relatives. Because it is not the FDA that becomes the victim of a lawsuit, it is the hospitals. Lawyers will never directly accuse a hospital of not implementing the NGAL test as long as the FDA has not approved the test, but they will accuse hospitals of not monitoring well enough, being too slow to react, etc. Lawyers will not use the words NGAL test, but everything else that revolves around the NGAL test's properties, and in this way, accuse hospitals of not being able to react as quickly as the NGAL test. As you can see, it's about large sums of money. To avoid the feared lawsuits and settlements, there is a grey zone that both BP and the hospitals are treading in on tiptoes. Hospitals large enough to have an advanced laboratory can get permission to introduce the NGAL test into their treatment systems, but only approved for research (RUO); every time hospitals use this test on their patients, it is naturally only for research. Hospitals will integrate the NGAL test into their treatment system, but only for research, naturally, to avoid lawsuits and settlements. The above also answers another wonder of mine: how can it be that there is strong growth in the USA when it is only for research? That is because those hospitals that have an advanced enough laboratory to help Bioporto in research also secretly use the test on all their other patients where the test is beneficial. The above is the reason why both PME and CB only come with some mumbling and incomprehensible words as to why RUO is good for BP's earnings. The FDA is naturally aware of this, but as long as the NGAL test saves lives and health, the bear will remain in its den.·3 t sittenSuch rubbish. It's blatantly obvious that everything you write is something you uncritically get from AI, which, so to speak, is trained in the USA, where one cannot say anything without also talking about lawsuits. In both BP and stenocare, you constantly babble about lawsuits. Only with an AI crash course in FDA did you delude yourself into thinking you understood FDA's complicated decision-making process and that on that basis you could predict that ngal would get a faster path. You were wrong because you didn't have the necessary insight to conclude as you did. No one has become a professor just by googling, either. It's not about conspiracy. It's about learning your own limitations and learning to use AI and Google with care.
- ·16 t sittenTo those of you who have a lot of money tied up in bioporto. Then I can't help but think that if it's going to take 2 years before anything happens with potential approvals, stock price increases, etc., then the money could be invested in many other things in the meantime? Economically speaking, it probably doesn't make much sense to have the money "standing still"? Because the stock price will probably hardly climb significantly before 2028 if things go as bioporto hopes? Anyone who wants to enlighten me on what they think? 🤔·4 t sittenNo, I don't agree with that. The only thing that can truly destroy Bioporto at this share price level is if the adult study fails.·4 t sitten · MuokattuPm_invest It's good to have different assessments. I now see the upcoming Kdigo as something investors attach great value to, both up and down. But I certainly find it interesting that you don't think it will affect the price. We will soon get an answer.
- ·22 t sittenCongratulations to CEO, Carsten Buhl, who in approx. 6 months has delivered 2 postponements of the financial target for cash flow Original plan H2 2027 1st postponement H1 2028 2nd postponement H2 2028 How many more can Carsten possibly manage to deliver in the coming 24 months...... 1, 2 or 3? The clock is ticking and patent expiry is getting closer and closer, while BP is burning millions.·21 t sittenProgression, there is a reason why very many small investors lose money, one of them is that many small investors are not at all interested in facts but only in hearing what they want to hear.
- ·23 t sittenPeople can view today's announcement as positive or negative depending on why one has invested in BioPorto. I clearly choose to see it from the positive side, as FDA has indicated that the regulatory path BioPorto has followed in their pre-sub study is the right path. Since the adult area is large, very large, FDA has recommended that in the validation study, the number of test subjects be increased from 500 to 900, which will of course push the timeline and cost extra money. I note here that they do not mention an emission, but rather will save their way out of the extra 20 million and if necessary seek credit possibilities for any remainder. It is not Trump/USA against BioPorto. It is a medical professional assessment made by FDA, and of course BioPorto chooses to cooperate regarding this. If one believes in the case, it can only be seen positively, as by complying with FDA, one is more certain of approval when the time comes, precisely because of a stronger study with more test subjects involved. The next milestone is the publication of KDIGO guidelines.·22 t sittenThat's probably the only thing you don't do…you exclusively post comments that are full of speculations and guesswork and it's clear to see you do everything to belittle others and the company…without anything to back it up.
- ·1 päivä sittenBioPorto plans U.S. adult validation study after feedback from the U.S. Food and Drug Administration (FDA) today at 12:28 ∙ GlobeNewswire https://www.globenewswire.com/news-release/2026/06/09/3308648/0/en/bioporto-initiates-u-s-adult-validation-study-following-u-s-food-and-drug-administration-fda-feedback.html·22 t sittenI am speechless that 3D continues to comment totally uncritically on the "big" journey and refuses to talk about risk. Watch out for your money out there and remember to be critical when you read "biased" posts in here. Let me remind you that 3D talked about SAS and the company's great future, as a shareholder (!), all while the share price was heading towards 0. He refused to acknowledge all talk about the stock potentially becoming worthless. It is shocking.·22 t sittenThere is nothing, as in absolutely nothing factual whatsoever, in your posts/comments here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 825 | - | - | ||
| 279 | - | - | ||
| 15 | - | - | ||
| 350 | - | - | ||
| 225 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 172 592 | 172 592 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 172 592 | 172 592 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
20 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·4 t sittenOnly for those of you who share my interest in finding out what hospitals do to avoid being sued. Everyone else stop reading. Now the penny has finally dropped for me. I have finally gotten an answer as to why it is best to sell the NGAL test as RUO in the USA at the moment. The above is a question we investors have never had answered, even though we ask about it often. Now that the FDA has done the unthinkable, kicking KDIGO's strong recommendations to the curb (see link from previous post) and due to political pressure from Donald Trump (see link from previous post) delaying the NGAL test for adults from being approved in the USA. I have dug a bit to find out if there is anything hospitals will do to avoid lawsuits from patients and relatives. Because it is not the FDA that becomes the victim of a lawsuit, it is the hospitals. Lawyers will never directly accuse a hospital of not implementing the NGAL test as long as the FDA has not approved the test, but they will accuse hospitals of not monitoring well enough, being too slow to react, etc. Lawyers will not use the words NGAL test, but everything else that revolves around the NGAL test's properties, and in this way, accuse hospitals of not being able to react as quickly as the NGAL test. As you can see, it's about large sums of money. To avoid the feared lawsuits and settlements, there is a grey zone that both BP and the hospitals are treading in on tiptoes. Hospitals large enough to have an advanced laboratory can get permission to introduce the NGAL test into their treatment systems, but only approved for research (RUO); every time hospitals use this test on their patients, it is naturally only for research. Hospitals will integrate the NGAL test into their treatment system, but only for research, naturally, to avoid lawsuits and settlements. The above also answers another wonder of mine: how can it be that there is strong growth in the USA when it is only for research? That is because those hospitals that have an advanced enough laboratory to help Bioporto in research also secretly use the test on all their other patients where the test is beneficial. The above is the reason why both PME and CB only come with some mumbling and incomprehensible words as to why RUO is good for BP's earnings. The FDA is naturally aware of this, but as long as the NGAL test saves lives and health, the bear will remain in its den.·3 t sittenSuch rubbish. It's blatantly obvious that everything you write is something you uncritically get from AI, which, so to speak, is trained in the USA, where one cannot say anything without also talking about lawsuits. In both BP and stenocare, you constantly babble about lawsuits. Only with an AI crash course in FDA did you delude yourself into thinking you understood FDA's complicated decision-making process and that on that basis you could predict that ngal would get a faster path. You were wrong because you didn't have the necessary insight to conclude as you did. No one has become a professor just by googling, either. It's not about conspiracy. It's about learning your own limitations and learning to use AI and Google with care.
- ·16 t sittenTo those of you who have a lot of money tied up in bioporto. Then I can't help but think that if it's going to take 2 years before anything happens with potential approvals, stock price increases, etc., then the money could be invested in many other things in the meantime? Economically speaking, it probably doesn't make much sense to have the money "standing still"? Because the stock price will probably hardly climb significantly before 2028 if things go as bioporto hopes? Anyone who wants to enlighten me on what they think? 🤔·4 t sittenNo, I don't agree with that. The only thing that can truly destroy Bioporto at this share price level is if the adult study fails.·4 t sitten · MuokattuPm_invest It's good to have different assessments. I now see the upcoming Kdigo as something investors attach great value to, both up and down. But I certainly find it interesting that you don't think it will affect the price. We will soon get an answer.
- ·22 t sittenCongratulations to CEO, Carsten Buhl, who in approx. 6 months has delivered 2 postponements of the financial target for cash flow Original plan H2 2027 1st postponement H1 2028 2nd postponement H2 2028 How many more can Carsten possibly manage to deliver in the coming 24 months...... 1, 2 or 3? The clock is ticking and patent expiry is getting closer and closer, while BP is burning millions.·21 t sittenProgression, there is a reason why very many small investors lose money, one of them is that many small investors are not at all interested in facts but only in hearing what they want to hear.
- ·23 t sittenPeople can view today's announcement as positive or negative depending on why one has invested in BioPorto. I clearly choose to see it from the positive side, as FDA has indicated that the regulatory path BioPorto has followed in their pre-sub study is the right path. Since the adult area is large, very large, FDA has recommended that in the validation study, the number of test subjects be increased from 500 to 900, which will of course push the timeline and cost extra money. I note here that they do not mention an emission, but rather will save their way out of the extra 20 million and if necessary seek credit possibilities for any remainder. It is not Trump/USA against BioPorto. It is a medical professional assessment made by FDA, and of course BioPorto chooses to cooperate regarding this. If one believes in the case, it can only be seen positively, as by complying with FDA, one is more certain of approval when the time comes, precisely because of a stronger study with more test subjects involved. The next milestone is the publication of KDIGO guidelines.·22 t sittenThat's probably the only thing you don't do…you exclusively post comments that are full of speculations and guesswork and it's clear to see you do everything to belittle others and the company…without anything to back it up.
- ·1 päivä sittenBioPorto plans U.S. adult validation study after feedback from the U.S. Food and Drug Administration (FDA) today at 12:28 ∙ GlobeNewswire https://www.globenewswire.com/news-release/2026/06/09/3308648/0/en/bioporto-initiates-u-s-adult-validation-study-following-u-s-food-and-drug-administration-fda-feedback.html·22 t sittenI am speechless that 3D continues to comment totally uncritically on the "big" journey and refuses to talk about risk. Watch out for your money out there and remember to be critical when you read "biased" posts in here. Let me remind you that 3D talked about SAS and the company's great future, as a shareholder (!), all while the share price was heading towards 0. He refused to acknowledge all talk about the stock potentially becoming worthless. It is shocking.·22 t sittenThere is nothing, as in absolutely nothing factual whatsoever, in your posts/comments here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 825 | - | - | ||
| 279 | - | - | ||
| 15 | - | - | ||
| 350 | - | - | ||
| 225 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 172 592 | 172 592 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 172 592 | 172 592 | 0 | 0 |